Prognostic and Predictive Value of Pretreatment Derived Neutrophil-to-Lymphocyte Ratio in Non-Small-Cell Lung Cancer Patients Treated with an Immune Checkpoint Inhibitor

作     者：John Kucharczyk Caitlin Sullivan Jonathan Lu Andrew Kolomensky Edward Peters Marc R. Matrana 

作者机构：NYU Winthrop Hospital Internal Medicine Residency Program NYU Winthrop Hospital Mineola NY USA The University of Queensland School of Medicine Ochsner Clinical School New Orleans LA USA Ochsner Medical Oncology Fellowship Program Ochsner Clinic Foundation New Orleans LA USA Louisiana State University School of Public Health New Orleans LA USA Ochsner Cancer Institute Ochsner Clinic Foundation New Orleans LA USA 

出 版 物：《Journal of Cancer Therapy》 (癌症治疗（英文）)

年 卷 期：2018年第9卷第1期

页      面：23-34页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Clinical Marker PD-1 Inhibitor Immunotherapy Nivolumab Pembrolizumab 

摘      要：Background: Immune checkpoint inhibitors produce prolonged responses in select non-small cell lung cancer (NSCLC) patients, however the identification of patients most likely to benefit is difficult. Pretreatment derived neutrophil-to-lymphocyte ratio (dNLR) is an easily calculated marker available in routine clinical care that has shown prognostic value in many cancer treatment settings, but its association with survival in NSCLC patients treated with immune-checkpoint inhibitors is less understood. Patients and Methods: We retrospectively reviewed 72 NSCLC patients receiving either nivolumab or pembrolizumab between 3/1/15 and 3/1/17 with a median follow-up time of 5.1 months. Patients were compared using Cox proportional hazards models to detect an association between pretreatment dNLR 3 vs ≥3 on overall survival (OS), progression-free survival (PFS) and overall response rate. Results: Median age was 65 (range: 41 - 86), 65% were male, 40% received ≥ 2 prior systemic therapies and 14% had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥ 2. Pretreatment dNLR ≥ 3 was independently associated with shortened OS (median 3.6 vs 8.5 months;HR: 5.4;95% CI: 2.0 - 14.6;p = 0.001) and PFS (median 2.1 vs 3.4;HR: 2.3;95% CI: 1.1 - 4.8;p = 0.027). Conclusion: Pretreatment dNLR ≥ 3 was independently associated with inferior survival in NSCLC treated with immune checkpoint inhibitors in routine practice. Prospective verification of this marker is warranted as it could serve as an inexpensive and widely-available marker for identifying NSCLC patients most likely to benefit from PD-1 inhibitors.